METHOD AND MEANS FOR MONITORING OF TISSUE HOMEOSTASIS IN ORGANISM Russian patent published in 2017 - IPC G01N33/533 

FIELD: medicine.

SUBSTANCE: method includes the following steps of: a) provision of a biological sample for testing from the said subject. This sample contains circulating tissue macrophages (CTM); b) staining of the said CTM using a panel of differentially labeled various antibodies against CD14, CD16, CD300e, CD36, and HLADR reference markers to identify and count various CTM subpopulations; c) CTM fixation, permeabilization and staining using one or more antibodies to detect against one or more epitopes of at least one protease-induced protein fragment resulting from intracellular degradation of non-CTM protein, individual STMs in tissues from which they occur, thereby identifying at least one subpopulation of circulating tissue-specific macrophages (CTSM). Further, a multiparametric flow cytometry analysis of the said stained CTM and CTSM is performed by selectively passing the CD14, CD16, CD300e, CD36 and HLADR reference markers to determine the number of signals of each specific labeled antibody bound to individual cells. The relative and absolute number of individual cells in each CTM subpopulation and each specific CTSM subpopulation that express each of the measured intracellular epitopes are determined. Calculation of the relative and absolute number of cells is carried out in each CTM subpopulation and each specific CTSM subpopulation, each of which derives from various normal and altered tissues, as determined by the assayed set of individual protease-induced protein fragments. Determination is made of the amount of antibody-associated signal associated with each individual assayed intracellular peptide to produce the CTSM staining profile. The test CTSM staining profile is compared to the normal CTSM staining profile for each assayed tissue. The increased number of CTSM indicates the presence of the disease. The group of inventions also refers to a kit for early diagnosis and monitoring of a disease in a subject using circulating tissue macrophages.

EFFECT: use of this group of inventions allows early diagnostics and monitoring of the disease using circulating tissue macrophages based on the CD14, CD16, CD300e, CD36 and HLADR reference markers.

23 cl, 2 tbl, 2 ex, 7 dwg